Riferimenti bibliografci
1. Alisky, J.M. et al. Transduction of murine cerebellar neurons withrecombinant FIV and AAV5 vectors. Neuroreport11, 2669-73 (2000). 2. Andersen, H., Dempsey, D., Chervenak, R. & Jennings, S.R.
Expression of intracellular IFN-gamma in HSV-1-specific CD8+ T cells identifies distinct responding subpopulations during the primary response to infection. J Immunol165, 2101-7 (2000).
3. Aymard, M. [Current epidemiology of herpes]. Pathol Biol (Paris) 50, 425-35 (2002).
4. Benedetti, J.K., Zeh, J. & Corey, L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann
Intern Med131, 14-20 (1999).
5. Benihoud, K., Yeh, P. & Perricaudet, M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol10, 440-7 (1999).
6. Benihoud, K., Yeh, P. & Perricaudet, M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol10, 440-7 (1999).
7. Boursnell, M.E. et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis175, 16-25 (1997).
8. Brittle. Current Herpes Simplex Virus Vaccine Approaches. US
Infectious Disease (2006).
9. Burke, C.J., Hsu, T.A. & Volkin, D.B. Formulation, stability, and delivery of live attenuated vaccines for human use. Crit Rev Ther Drug
Carrier Syst16, 1-83 (1999).
10. Burton, E.A. et al. Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells19, 358-77 (2001).
11. Chahlavi, A., Rabkin, S., Todo, T., Sundaresan, P. & Martuza, R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6, 1751-8 (1999).
12. Connolly, J.B. Lentiviruses in gene therapy clinical research. Gene
13. Corey, L. Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. J Infect Dis195, 1242-4 (2007). 14. Curran, M.A., Kaiser, S.M., Achacoso, P.L. & Nolan, G.P. Efficient
transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther1, 31-8 (2000).
15. Da Costa, X.J., Bourne, N., Stanberry, L.R. & Knipe, D.M. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology232, 1-12 (1997). 16. De Palma, M., Venneri, M.A., Roca, C. & Naldini, L. Targeting
exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9, 789-95 (2003).
17. Delenda, C. Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med6 Suppl 1, S125-38 (2004).
18. Epstein, A.L., Marconi, P., Argnani, R. & Manservigi, R. HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther5, 445-58 (2005).
19. Flotte, T.R. et al. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther15, 229-41 (2007).
20. Freeman, E.E. & Glynn, J.R. Factors affecting HIV concordancy in married couples in four African cities. Aids18, 1715-21 (2004).
21. Freeman, E.E. et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids20, 73-83 (2006).
22. Friedmann, T. & Yee, J.K. Pseudotyped retroviral vectors for studies of human gene therapy. Nat Med1, 275-7 (1995).
23. Graham, F.L. & Prevec, L. Methods for construction of adenovirus vectors. Mol Biotechnol3, 207-20 (1995).
24. Graham, F.L., Smiley, J., Russell, W.C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
J Gen Virol36, 59-74 (1977).
25. Johnston, J.C. et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus
vectors. J Virol73, 4991-5000 (1999).
26. Jones, C.A. & Cunningham, A.L. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
Herpes11, 12-7 (2004).
27. Kang, Y. et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol 76, 9378-88 (2002).
28. Kang, Y. et al. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood106, 1552-8 (2005).
29. Kay, M.A., Glorioso, J.C. & Naldini, L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat
Med7, 33-40 (2001).
30. Koelle, D.M. & Corey, L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16, 96-113 (2003).
31. Krone, M.R. et al. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. Clin Infect Dis30, 261-7 (2000). 32. Kumaraguru, U., Gierynska, M., Norman, S., Bruce, B.D. & Rouse,
B.T. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J Virol76, 136-41 (2002).
33. Kumaraguru, U. & Rouse, B.T. Application of the intracellular gamma interferon assay to recalculate the potency of CD8(+) T-cell responses to herpes simplex virus. J Virol74, 5709-11 (2000).
34. Kyrkanides, S., Miller, J.H. & Federoff, H.J. Systemic FIV vector administration: transduction of CNS immune cells and Purkinje neurons. Brain Res Mol Brain Res119, 1-9 (2003).
35. Loewen, N. et al. Long-term retinal transgene expression with FIV versus adenoviral vectors. Mol Vis10, 272-80 (2004).
36. Lombardi, S. et al. Detection of feline immunodeficiency virus p24 antigen and p24-specific antibodies by monoclonal antibody-based assays. J Virol Methods46, 287-301 (1994).
recombinant feline immunodeficiency virus vectors. Hum Gene Ther 13, 689-96 (2002).
38. Lusky, M. et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol72, 2022-32 (1998). 39. Madkan, V.K., Giancola, A.A., Sra, K.K. & Tyring, S.K. Sex differences
in the transmission, prevention, and disease manifestations of sexually transmitted diseases. Arch Dermatol142, 365-70 (2006).
40. Mangeot, P.E. et al. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther5, 283-90 (2002).
41. Meignier, B., Longnecker, R., Mavromara-Nazos, P., Sears, A.E. & Roizman, B. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology 162, 251-4 (1988).
42. Miao, C.H. et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 74, 3793-803 (2000).
43. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F.H. & Verma, I.M. Development of a self-inactivating lentivirus vector. J Virol 72, 8150-7 (1998).
44. Monahan, P.E. & Samulski, R.J. AAV vectors: is clinical success on the horizon? Gene Ther7, 24-30 (2000).
45. Morris, K.V., Gilbert, J., Wong-Staal, F., Gasmi, M. & Looney, D.J. Transduction of cell lines and primary cells by FIV-packaged HIV vectors. Mol Ther10, 181-90 (2004).
46. Nagot, N. et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med356, 790-9 (2007).
47. Nagot, N. et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med356, 790-9 (2007).
48. Naldini, L., Blomer, U., Gage, F.H., Trono, D. & Verma, I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl
Acad Sci U S A93, 11382-8 (1996).
latency-associated transcript sequences that protect from apoptosis mediated by a plasmid expressing caspase-8. J Neurovirol10, 260-5 (2004). 50. Pistello, M., Vannucci, L., Ravani, A., Bonci, F., Chiuppesi, F., Del
Santo, B., Freer, G. & Bendinelli, M. Steamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex
vivo dendritic cells and T lymphocytes. Submitted
51. Poeschla, E.M., Wong-Staal, F. & Looney, D.J. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med4, 354-7 (1998).
52. Puck, J.M. & Malech, H.L. Gene therapy for immune disorders: good news tempered by bad news. J Allergy Clin Immunol 117, 865-9 (2006).
53. Roest, R.W. et al. Genotypic analysis of sequential genital herpes simplex virus type 1 (HSV-1) isolates of patients with recurrent HSV-1 associated genital herpes. J Med Virol73, 601-4 (2004).
54. Sauter, S.L. & Gasmi, M. FIV vector systems. Somat Cell Mol Genet 26, 99-129 (2001).
55. Shah, K. & Breakefield, X.O. HSV amplicon vectors for cancer therapy.
Curr Gene Ther6, 361-70 (2006).
56. Siapati, E.K. et al. Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells. Mol Ther12, 537-46 (2005).
57. Smith, R.W., Malik, P. & Clements, J.B. The herpes simplex virus ICP27 protein: a multifunctional post-transcriptional regulator of gene expression. Biochem Soc Trans33, 499-501 (2005).
58. Stein, C.S. et al. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors.
Mol Ther3, 850-6 (2001).
59. Suligoi, B., Torri, A., Grilli, G., Tanzi, E. & Palu, G. Seroprevalence and seroincidence of herpes simplex virus type 1 and herpes simplex virus type 2 infections in a cohort of adolescents in Italy. Sex Transm
Dis31, 608-10 (2004).
60. Thomas, C.E., Ehrhardt, A. & Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4, 346-58
(2003).
61. Vyse, A.J. et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Infect76, 183-7 (2000).
62. Wald, A. Genital herpes. Clin Evid, 1416-25 (2002).
63. Wald, A. Genital HSV-1 infections. Sex Transm Infect 82, 189-90 (2006).
64. Wang, G. et al. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest104, R55-62 (1999).
65. Wang, S. & Vos, J.M. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol70, 8422-30 (1996).
66. Weiss, H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes11 Suppl 1, 24A-35A (2004).
67. Whitley, R.J. & Roizman, B. Herpes simplex viruses: is a vaccine tenable? J Clin Invest110, 145-51 (2002).
68. Willett, B.J., Cannon, C.A. & Hosie, M.J. Expression of CXCR4 on feline peripheral blood mononuclear cells: effect of feline immunodeficiency virus infection. J Virol77, 709-12 (2003).
69. Xu, F. & Ulmer, J.B. Attenuated salmonella and Shigella as carriers for DNA vaccines. J Drug Target11, 481-8 (2003).
70. Zufferey, R., Donello, J.E., Trono, D. & Hope, T.J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73, 2886-92 (1999).
